MVM Partners LLP Closes Fund V
MVM Partners announces the closing of a $325 million healthcare fund, MVM V.
HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test
Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.
Vertos MOTION study enrollment complete
Vertos Medical completes enrollment in MOTION study of mild® procedure, a minimally invasive treatment for lumbar spinal stenosis
HLS Therapeutics announces Health Canada grants medical device license for CSAN PRONTO
HLS Therapeutics Inc. announces that Health Canada has granted a medical device license for the Athelas One WBC System, marketed as CSAN PRONTO, for use as a point-of-care device indicated for quantitative determination of white blood cells and neutrophil percentages in capillary or venous whole blood.
Valneva completes recruitment for phase 2 studies of its Lyme Disease vaccine candidate VLA15
Valneva has announced that it has completed patient recruitment of the Phase 2 studies for its Lyme disease vaccine candidate, VLA15.
Baxter announces acquisition of Cheetah Medical
Baxter International Inc., a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies
Zipline announces positive results from two significant clinical studies
ZipLine Medical, Inc. has announced publication of positive results from two significant clinical studies in two peer- reviewed journals demonstrating that use of Zip® Surgical Skin Closure leads to better clinical outcomes and healthcare cost savings than do surgical staples
Valneva reports strong operational performance and major corporate progress with H1 2019 results
Valneva has reported that its H1 2019 results are marked by strong operational performance and major corporate progress; regaining control of key R&D assets and strengthening its financial outlook with $23 million CEPI chikungunya grant
Valneva initiates second Phase II study for its Lyme Disease vaccine candidate
Valneva has announced the initiation of the second study of Phase 2 clinical development for its leading, unique Lyme disease vaccine candidate VLA15